Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of irinotecan hydrochloride liposome injection II in pancreatic cancer in China
ChiCTR2400082945Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of liposomal irinotecan in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Treatment-emergent adverse events. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
liposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400082945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082945.